Scarica l'app Stockscreener
0.6409
3.72%
-0.0238
Precedente Chiudi:
$0.6647
Aprire:
$0.66
Volume 24 ore:
641.53K
Relative Volume:
0.44
Capitalizzazione di mercato:
$163.77M
Reddito:
$175.04M
Utile/perdita netta:
$-44.52M
Rapporto P/E:
-1.2006
EPS:
-0.5338
Flusso di cassa netto:
$-56.05M
1 W Prestazione:
+8.25%
1M Prestazione:
-22.31%
6M Prestazione:
-40.74%
1 anno Prestazione:
+44.96%
Intervallo 1D:
$0.64
$0.6825
Intervallo di 1 settimana:
$0.571
$0.705
Portata 52W:
$0.4205
$2.05
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Nome
Adaptimmune Therapeutics Plc Adr
Settore
Industria
Telefono
44 1235 430000
Indirizzo
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Confronta ADAP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ADAP | 0.64 | 163.77M | 175.04M | -44.52M | -56.05M | -0.5338 |
| VRTX | 450.36 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.27 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.08 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.36 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.36 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-09 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-05-28 | Iniziato | Barclays | Underweight |
| 2020-04-22 | Iniziato | Mizuho | Neutral |
| 2019-08-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-05-31 | Iniziato | ROTH Capital | Buy |
| 2019-05-30 | Ripresa | Citigroup | Buy |
| 2019-05-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | Iniziato | Wells Fargo | Market Perform |
| 2016-10-24 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | Iniziato | Raymond James | Outperform |
| 2016-02-25 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | BofA/Merrill | Neutral |
| 2015-06-01 | Iniziato | Guggenheim | Buy |
| 2015-06-01 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Adaptimmune Therapeutics Plc Adr Borsa (ADAP) Ultime notizie
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register
Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa
Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com
Adaptimmune faces Nasdaq delisting over share price - Investing.com India
NVIDIA Corp (NVDA): Be Patient, You Will Learn - Stocks Register
Investing in HUYA Inc ADR (HUYA): What You Must Know - Knox Daily
Checking in on Blackstone Inc (BX) after recent insiders movement - Knox Daily
Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News
Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily
The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle
Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News
Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
A significant driver of top-line growth: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Analysts review Adaptimmune Therapeutics Plc ADR’s rating - Knox Daily
How should investors view Adaptimmune Therapeutics Plc ADR (ADAP)? - US Post News
Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily
Wall Street SWOT: Adaptimmune stock faces challenges despite FDA win - Investing.com
Stocks of Adaptimmune Therapeutics Plc ADR (ADAP) are poised to climb above their peers - SETE News
Insider Sale Alert: Gap, Inc. [GAP] – Is it Time to sell? - Knox Daily
Adaptimmune Therapeutics Plc ADR [ADAP] Piccina Cintia sells 24,531 Shares for $22814.0 - Knox Daily
Adaptimmune finalizes settlement with Genentech - Investing.com India
ADAP’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Ratios Uncovered: Breaking Down Adaptimmune Therapeutics Plc ADR (ADAP)’s Trailing Twelve Months Metrics - The Dwinnex
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Yahoo Finance UK
Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance: Is It Undervalued or Overvalued? - The InvestChronicle
Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily
Zumiez Inc’s latest rating changes from various analysts - Knox Daily
AdaptHealth Stock Earns RS Rating Upgrade - MSN
A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News
Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News
Director SIMON WILLIAM E JR acquire 45,000 shares of Douglas Emmett Inc [DEI] - Knox Daily
Buying Buzz: Noble Corp Plc [NE] 10% Owner APMH Invest A/S purchases 324,984 shares of the company - Knox Daily
There is no doubt that Adaptimmune Therapeutics Plc ADR (ADAP) ticks all the boxes. - SETE News
Analyzing Ratios: Adaptimmune Therapeutics Plc ADR (ADAP)’s Financial Story Unveiled - The Dwinnex
Adaptimmune Therapeutics Plc ADR (ADAP) stock analysis: A simple moving average approach - US Post News
A company insider recently sold 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP]. Should You Sale? - Knox Daily
EWCZ Shares Experience Decline in Value - Knox Daily
Natera Inc [NTRA] Shares Jump Approximately 97.71% Over the Year - Knox Daily
Adaptimmune Therapeutics Plc ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Premier Inc [PINC] Shares Fall -1.35 % on Thursday - Knox Daily
An analyst sees good growth prospects for Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News
Closing Figures: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.16, Down -4.13 - The Dwinnex
Analyzing Adaptimmune Therapeutics Plc ADR (ADAP) After Recent Trading Activity - Knox Daily
Adaptimmune Therapeutics Plc ADR (ADAP) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Market Recap Check: Adaptimmune Therapeutics Plc ADR (ADAP)’s Negative Finish at 1.24, Up/Down -6.77 - The Dwinnex
Adaptimmune Therapeutics Plc ADR: Rising -35.12% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
A closer look at Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price trends - US Post News
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
Adaptimmune Therapeutics Plc Adr Azioni (ADAP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):